DSI
ALXN

Daiwa SB Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Daiwa SB Investments’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,760
Closed -$245K – 186
2016
Q1 		$245K Buy
1,760
+440
+33% +$64.6K 0.06% 100
2015
Q4 		$252K Buy
1,320
+110
+9% +$19.2K 0.06% 104
2015
Q3 		$189K Hold
1,210
– – 0.04% 133
2015
Q2 		$219K Hold
1,210
– – 0.04% 146
2015
Q1 		$210K Sell
1,210
-140
-10% -$25.3K 0.04% 138
2014
Q4 		$250K Buy
+1,350
New +$250K 0.04% 127

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Daiwa SB Investments's ALXN Position: Q2 2016 in Review

Daiwa SB Investments sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 1,760 shares — an estimated $245K sold.

Daiwa SB Investments first reported a position in ALXN in Q4 2014 and held it in 6 quarters. The position peaked at $252K in Q4 2015. 534 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

  • Daiwa SB Investments reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Daiwa SB Investments sold 1,760 Alexion Pharmaceuticals shares in Q2 2016, an estimated $245K.
  • Daiwa SB Investments first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 6 quarters.
  • Daiwa SB Investments's Alexion Pharmaceuticals position peaked at $252K in Q4 2015.
  • 534 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Daiwa SB Investments's 13F filing for Q2 2016, filed 8 Jul 2016.